Syphilis Screening: Traditional vs. Reverse Algorithms, False Positives, and the SLE Connection

 

Syphilis Screening: Traditional vs. Reverse Algorithms, False Positives, and the SLE Connection

Two tests, two algorithms, one disease that's surging back—and the autoimmune pitfall that keeps tripping everyone up.

Syphilis is back. Rates in the US have been climbing steadily, congenital syphilis cases have skyrocketed, and the CDC has made this a public health priority. For NPs in primary care, prenatal care, and urgent care, understanding the screening algorithms isn't optional anymore—it's essential. And the fact that your lab may be using a different algorithm than the one you learned in school makes it even more critical to know what you're looking at.

The Two Categories of Tests

Before we get to algorithms, you need to understand the two fundamentally different types of syphilis tests:

Nontreponemal Tests (RPR, VDRL)

• Detect antibodies to cardiolipin-cholesterol-lecithin antigens released from damaged host cells and from T. pallidum itself
• NOT specific to syphilis—they detect tissue damage, not the organism
• Reported as a quantitative titer (1:2, 1:4, 1:8, etc.)
• Titers correlate with disease activity and are used to monitor treatment response
• A fourfold change in titer (two dilutions, e.g., 1:16 to 1:4) = clinically significant change
• Become negative after successful treatment in most patients (though some remain "serofast" at a low titer indefinitely)
• Can be falsely positive in many conditions (see pitfalls below)

Treponemal Tests (FTA-ABS, TP-PA, EIA/CIA)

• Detect antibodies specific to Treponema pallidum
• Confirm that a nontreponemal positive is real syphilis (traditional algorithm)
• OR serve as the initial screen (reverse algorithm)
• Remain positive for life in 75–85% of patients after treatment—they are NOT useful for monitoring treatment response
• Cannot distinguish active from past/treated infection on their own
• False positives can occur with Lyme disease and other non-syphilis treponemal infections

The Two Algorithms

Traditional Algorithm

Screen with a nontreponemal test, confirm with a treponemal test.

1. RPR or VDRL (screening)
2. ↓ If reactive:
3. Treponemal test (FTA-ABS or TP-PA) to confirm
4. ↓ Both reactive = syphilis (stage based on clinical findings and titer)

Pros: Familiar, cost-effective, fewer false-positive workups in low-prevalence settings. RPR titer immediately available for staging and monitoring.
Cons: Can miss early primary syphilis and late latent syphilis (RPR may be nonreactive). Higher false-positive rate for the screening step.

Reverse Algorithm

Screen with a treponemal test, then get a nontreponemal titer.

1. Treponemal immunoassay (EIA or CIA—automated) as the screen
2. ↓ If reactive:
3. RPR (quantitative titer) to assess disease activity
4. ↓ If RPR is also reactive = syphilis (stage and treat)
5. ↓ If RPR is nonreactive (discordant):
6. Second, different treponemal test (TP-PA) as tiebreaker

Pros: Automated, high-throughput, catches latent syphilis and previously treated cases that RPR would miss. More sensitive overall.
Cons: Generates more discordant results requiring tiebreaker testing. Can identify past treated syphilis (treponemal tests stay positive for life), leading to unnecessary workups and overtreatment if not interpreted carefully.

Know Your Lab

Find out which algorithm your lab uses. Many high-volume commercial labs have switched to the reverse algorithm because of automation. If you're interpreting results without knowing which algorithm generated them, you can easily misread what a "positive syphilis screen" means. Ask your lab.

Interpreting the Results: The Cheat Sheet

Nontreponemal (RPR/VDRL)	Treponemal (FTA-ABS/TP-PA/EIA)	Interpretation
Nonreactive	Not done or nonreactive	No syphilis detected. (But can miss very early primary syphilis—both tests may be negative in the first 1–2 weeks of chancre.)
Reactive	Reactive	Syphilis confirmed. Stage and treat based on clinical findings and RPR titer. Could be active or past inadequately treated infection.
Reactive	Nonreactive	Biologic false positive RPR. The patient does NOT have syphilis. Investigate causes (see pitfalls).
Nonreactive	Reactive	Discordant (reverse algorithm scenario). Could be: (1) past treated syphilis (most common), (2) late latent syphilis with waning RPR, (3) very early primary syphilis, or (4) false-positive treponemal screen. Resolve with a second, different treponemal test (TP-PA).
Low-titer reactive (1:1–1:2)	Reactive	Could be serofast state (patient previously treated, RPR won't fully decline) or early/late infection. Correlate with treatment history and clinical exam.

The Pitfalls: Where NPs Get Tripped Up

1. The Biologic False-Positive RPR—and the SLE Connection

This is the pitfall that ties directly into the autoimmune series. The RPR and VDRL use cardiolipin as their antigen. Patients with antiphospholipid antibodies—including anticardiolipin antibodies—will have a false-positive RPR/VDRL because the test is detecting their autoantibodies, not a syphilis infection.

Conditions that cause biologic false-positive RPR/VDRL:

• SLE — the classic autoimmune culprit; up to 10–20% of SLE patients may have a false-positive RPR
• Antiphospholipid syndrome — by definition, these patients have anticardiolipin antibodies
• Pregnancy
• HIV infection
• IV drug use
• Other infections: hepatitis, EBV, malaria, tuberculosis, endocarditis
• Chronic liver disease
• Advanced age
• Recent vaccination

The Autoimmune Pearl

A positive RPR with a negative treponemal test in a young woman should make you think about SLE and antiphospholipid syndrome, not just dismiss it as a lab error. In fact, a biologic false-positive syphilis test was historically one of the earliest recognized clues to antiphospholipid antibody positivity. If you see this pattern, check an antiphospholipid panel (lupus anticoagulant, anticardiolipin, anti-β2GPI) and consider ANA testing.

2. The "Discordant Reverse Algorithm" Trap

With the reverse algorithm, you'll frequently encounter the scenario: treponemal screen reactive, RPR nonreactive. This generates a lot of confusion and unnecessary treatment. In most cases, this represents a patient with past, adequately treated syphilis whose treponemal antibodies persist for life. The key is the tiebreaker TP-PA:

• TP-PA reactive: The patient had real syphilis at some point. If no history of treatment, treat for late latent syphilis. If previously treated, no action needed (unless reexposure is suspected).
• TP-PA nonreactive: The original treponemal screen was a false positive. No syphilis. No treatment.

3. RPR Titers Are Not Interchangeable with VDRL

RPR and VDRL are both nontreponemal tests, but their titers are not directly comparable. An RPR of 1:8 and a VDRL of 1:8 may not represent the same antibody level. Always use the same test (and ideally the same lab) for serial monitoring. A fourfold change (two dilutions) is required to call a result clinically significant.

4. The Prozone Phenomenon

In secondary syphilis, antibody levels can be so high that they overwhelm the nontreponemal assay, causing a false-negative RPR (or a paradoxically low titer). This is called the prozone effect. If you have a patient with classic secondary syphilis symptoms (diffuse rash including palms/soles, mucous patches, condylomata lata) and a nonreactive or weakly reactive RPR, request that the lab perform serial dilutions to unmask a high-titer positive.

Clinical Pearl

If it looks like secondary syphilis clinically but the RPR is negative or suspiciously low, call your lab and ask for dilution testing. The prozone phenomenon is rare but real, and missing secondary syphilis has serious consequences.

5. Treponemal Tests Stay Positive for Life

Once treated, treponemal tests (FTA-ABS, TP-PA, EIA) remain reactive in 75–85% of patients forever. This does NOT indicate reinfection or treatment failure. Only 15–25% of patients treated during primary syphilis will eventually revert to seronegative. Do not use treponemal tests to monitor treatment response. Use the RPR titer.

6. Very Early Primary Syphilis Can Be Seronegative

In the first 1–2 weeks after a chancre appears, both nontreponemal and treponemal tests may still be negative. If you see a painless genital ulcer consistent with a chancre, treat empirically and retest in 2–4 weeks. Don't let a negative serology stop you from treating a clinical primary syphilis.

7. The Serofast State

Some patients, even after adequate treatment, will maintain a persistently low-titer RPR (typically 1:1 to 1:4) indefinitely. This is called the serofast state and does NOT indicate treatment failure or reinfection. It's more common in patients treated for late-stage syphilis. A serofast patient should be monitored but does not need retreatment unless there's clinical evidence of active disease or a fourfold rise in titer.

8. Pregnancy: Test Three Times

Given the surge in congenital syphilis, current guidelines (CDC, ACOG) now recommend screening pregnant patients three times: at the first prenatal visit, early in the third trimester (~28 weeks), and at delivery. This is non-negotiable. Congenital syphilis is devastating and entirely preventable with timely treatment.

When Should NPs Order Syphilis Testing?

Test When You See

• Any painless genital, anal, or oral ulcer (suspect primary syphilis)
• Diffuse rash involving palms and soles (suspect secondary syphilis)
• Mucous patches, condylomata lata, patchy alopecia
• All pregnant patients (three times during pregnancy)
• All patients diagnosed with another STI (HIV, gonorrhea, chlamydia)
• MSM (men who have sex with men)—per CDC, screen at least annually
• HIV-positive patients—screen at baseline and annually
• New sexual partner evaluation or sexual assault follow-up
• Unexplained neurologic symptoms in a patient with history of syphilis or risk factors
• Biologic false-positive RPR as part of a broader autoimmune workup (check aPL panel)

The SLE/APS Connection: A Summary for Your Autoimmune Patients

Tying It Together

In a patient with SLE or suspected antiphospholipid syndrome:

• A positive RPR/VDRL + negative treponemal test = biologic false positive, NOT syphilis. This is a clue to check antiphospholipid antibodies.
• Conversely, a positive treponemal test in an SLE patient should be taken seriously—the treponemal test is specific for syphilis and is NOT affected by antiphospholipid antibodies.
• The biologic false-positive syphilis test was historically one of the earliest recognized markers of antiphospholipid antibodies—before aPL assays existed, this was how clinicians first identified the autoantibodies that would later define antiphospholipid syndrome.
• Always confirm a reactive RPR with a treponemal test before diagnosing syphilis in an autoimmune patient. And always investigate a false-positive RPR for underlying autoimmune disease in a young patient.

Quick-Reference: The Decision Matrix

Scenario	What to Do
RPR reactive, treponemal reactive	Syphilis confirmed. Stage and treat. Monitor RPR titers.
RPR reactive, treponemal nonreactive	Biologic false positive. No syphilis. Investigate: SLE? APS? Pregnancy? Infection?
Treponemal screen reactive, RPR nonreactive (reverse algorithm)	Order TP-PA tiebreaker. If TP-PA reactive + no treatment history → treat for late latent. If TP-PA nonreactive → false-positive screen.
Previously treated, low-titer serofast RPR (1:1–1:4)	Monitor. No retreatment unless fourfold rise or clinical symptoms.
Clinical chancre, serology negative	Treat empirically. Retest in 2–4 weeks. Very early primary can be seronegative.
Pregnant patient	Screen at first visit, ~28 weeks, and delivery. Treat immediately if positive. Don't wait for confirmatory testing to treat in pregnancy.

Bottom Line

Syphilis testing is not complicated once you understand the two test types and the two algorithms. The critical points: know which algorithm your lab uses, never diagnose syphilis on a nontreponemal test alone, never use a treponemal test to monitor treatment, and always investigate a biologic false-positive RPR for underlying autoimmune disease. For your autoimmune patients, the RPR is a test that speaks two languages—infection and autoimmunity—and knowing which one it's speaking requires the treponemal test as the translator.

And with congenital syphilis surging, screen every pregnant patient three times. No exceptions.

Stay sharp out there.